Christine Dehner

765 total citations
19 papers, 520 citations indexed

About

Christine Dehner is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Christine Dehner has authored 19 papers receiving a total of 520 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 5 papers in Immunology. Recurrent topics in Christine Dehner's work include CAR-T cell therapy research (17 papers), Lymphoma Diagnosis and Treatment (6 papers) and Biosimilars and Bioanalytical Methods (4 papers). Christine Dehner is often cited by papers focused on CAR-T cell therapy research (17 papers), Lymphoma Diagnosis and Treatment (6 papers) and Biosimilars and Bioanalytical Methods (4 papers). Christine Dehner collaborates with scholars based in United States. Christine Dehner's co-authors include Jeremy S. Abramson, Tanya Siddiqi, David G. Maloney, Gary Calandra, W. Conrad Liles, Hal E. Broxmeyer, Jeff Christensen, Elin Rodger, Karin Badel and Brent L. Wood and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Transfusion.

In The Last Decade

Christine Dehner

18 papers receiving 512 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christine Dehner United States	11	402	153	152	112	88	19	520
Houston Holmes United States	12	319 0.8×	202 1.3×	146 1.0×	119 1.1×	88 1.0×	39	540
Hien Liu United States	11	449 1.1×	144 0.9×	153 1.0×	67 0.6×	156 1.8×	62	594
Alessandro Previtali United States	7	257 0.6×	101 0.7×	111 0.7×	76 0.7×	84 1.0×	18	374
Gloria Iacoboni Spain	16	588 1.5×	73 0.5×	294 1.9×	111 1.0×	102 1.2×	65	730
Dorothea Wessiepe Germany	5	497 1.2×	117 0.8×	126 0.8×	198 1.8×	79 0.9×	5	669
Alberto Mussetti Spain	13	251 0.6×	196 1.3×	82 0.5×	97 0.9×	96 1.1×	51	435
Alessandro Crotta United States	7	273 0.7×	99 0.6×	121 0.8×	55 0.5×	48 0.5×	26	369
Paul Maciocia United Kingdom	9	378 0.9×	85 0.6×	121 0.8×	153 1.4×	131 1.5×	23	504
Martina Pennisi Italy	12	520 1.3×	88 0.6×	81 0.5×	92 0.8×	103 1.2×	29	612
LaQuisa Hill United States	11	265 0.7×	83 0.5×	66 0.4×	132 1.2×	72 0.8×	26	368

Countries citing papers authored by Christine Dehner

Since Specialization

Citations

This map shows the geographic impact of Christine Dehner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine Dehner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine Dehner more than expected).

Fields of papers citing papers by Christine Dehner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine Dehner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine Dehner. The network helps show where Christine Dehner may publish in the future.

Co-authorship network of co-authors of Christine Dehner

This figure shows the co-authorship network connecting the top 25 collaborators of Christine Dehner. A scholar is included among the top collaborators of Christine Dehner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine Dehner. Christine Dehner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Garcia, Jacob, et al.. (2024). A Phase 1, Multicenter, Open-Label Study of UB-VV111 in Combination with Rapamycin in Relapsed/Refractory CD19+ B-Cell Malignancies. Blood. 144(Supplement 1). 1750.1–1750.1. 2 indexed citations

Abramson, Jeremy S., M. Lia Palomba, Leo I. Gordon, et al.. (2023). Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 143(5). 404–416. 68 indexed citations

Wang, Michael, Tanya Siddiqi, Leo I. Gordon, et al.. (2023). Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. Journal of Clinical Oncology. 42(10). 1146–1157. 41 indexed citations

Abramson, Jeremy S., Leo I. Gordon, Matthew A. Lunning, et al.. (2022). Two-Year (yr) Follow-up (FU) of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL). Transplantation and Cellular Therapy. 28(3). S55–S56.

Abramson, Jeremy S., M. Lia Palomba, Leo I. Gordon, et al.. (2021). Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL). Blood. 138(Supplement 1). 2840–2840. 40 indexed citations

Patrick, Donald L., Annette Powers, Yeonhee Kim, et al.. (2021). Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma. Blood Advances. 5(8). 2245–2255. 25 indexed citations

Abramson, Jeremy S., Tanya Siddiqi, Jacob Garcia, et al.. (2021). Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Advances. 5(6). 1695–1705. 23 indexed citations

Palomba, Maria Lia, Leo I. Gordon, Tanya Siddiqi, et al.. (2020). Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001. Blood. 136(Supplement 1). 10–11. 47 indexed citations

Patrick, Donald L., Annette Powers, Monika Parisi, et al.. (2019). Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001. Blood. 134(Supplement_1). 66–66. 8 indexed citations

10.

Abramson, Jeremy S., Maria Lia Palomba, Jon Arnason, et al.. (2019). Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.. Journal of Clinical Oncology. 37(15_suppl). 7515–7515. 13 indexed citations

11.

Patrick, Donald L., Karen Chung, Yeonhee Kim, et al.. (2019). TRANSCEND NHL 001: Health-related quality of life (HRQL) and symptom (Sx) impact in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017).. Journal of Clinical Oncology. 37(15_suppl). e19052–e19052. 3 indexed citations

12.

Wang, Michael, Leo I. Gordon, Maria Lia Palomba, et al.. (2019). Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001.. Journal of Clinical Oncology. 37(15_suppl). 7516–7516. 12 indexed citations

13.

Abramson, Jeremy S., Tanya Siddiqi, Jacob Garcia, et al.. (2019). Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017) in TRANSCEND NHL 001.. Journal of Clinical Oncology. 37(15_suppl). 6637–6637. 5 indexed citations

14.

Siddiqi, Tanya, Jacob Garcia, Christine Dehner, et al.. (2018). Estimation of the Resource Utilization and Costs of Cytokine Release Syndrome Observed in the Transcend-NHL Clinical Trial: A Micro-Costing Study. Blood. 132(Supplement 1). 319–319. 6 indexed citations

15.

Palomba, M. Lia, Jacob Garcia, Lei Wang, et al.. (2018). TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 132(Supplement 1). 3545–3545. 7 indexed citations

16.

Abramson, Jeremy S., Tanya Siddiqi, M. Lia Palomba, et al.. (2018). High Durable CR Rates and Preliminary Safety Profile for JCAR017 in R/R Aggressive B-NHL (TRANSCEND NHL 001 Study): A Defined Composition CD19-Directed CAR T Cell Product with Potential for Outpatient Administration. Biology of Blood and Marrow Transplantation. 24(3). S25–S25. 11 indexed citations

17.

Abramson, Jeremy S., Tanya Siddiqi, Maria Lia Palomba, et al.. (2018). High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration.. Journal of Clinical Oncology. 36(5_suppl). 120–120. 24 indexed citations

18.

Liles, W. Conrad, Elin Rodger, Hal E. Broxmeyer, et al.. (2005). Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 45(3). 295–300. 177 indexed citations

19.

Dugan, Michael J., Luke P. Akard, James Thompson, et al.. (2004). Treatment with AMD3100 in Multiple Myeloma or Non-Hodgkin’s Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given with a Mobilizing Regimen of Chemotherapy and G-CSF.. Blood. 104(11). 2860–2860. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact